Preclinical evaluation of IGF1 therapy for traumatic brain injury

Traumatic brain injury affliects an estimated 1.5 million people each year in the US. Survivors often suffer persistent neurological dysfunction, compromising their quality of life and productive. The central hypothesis of this proposal is that treatment with insulin-lke growth factor (IGF-1) will improve neurobehavioral function through teh attenuation of neurovascular damage and the augmentation of post-traumatic neurogenesis and angiogenesis.